Leucine-enriched Formulas in Patients With Tumor-induced Sarcopenia
NCT ID: NCT05837741
Last Updated: 2023-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
48 participants
INTERVENTIONAL
2021-03-01
2021-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of an Oral Nutritional Supplement on Muscle Mass During Anticancer Treatment
NCT05648955
Omega-3 Fatty Acids and Nutritional Support in Gastrointestinal Cancer
NCT06015971
Nutritional Status in Retroperitoneal Sarcoma.
NCT03877588
the Safety and Effectiveness of Protein Supplements on Cancer Patients With Nutritional Risk and Malnutrition
NCT05802381
Prevention of Cancer-associated Malnutrition Through Oral Nutritional Supplements
NCT02312674
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard hypercaloric, hyperproteic oral supplement
Patients will receive 2 supplements per day (Standard hypercaloric, hyperproteic oral supplement)
Standard hypercaloric hyperproteic oral nutritional supplement
Patients will receive nutritional support with Standard hypercaloric hyperproteic oral nutritional supplement
Leucin-enriched hypercaloric, hyperproteic oral supplement
Patients will receive 2 supplements per day (Leucin-enriched hypercaloric, hyperproteic oral supplement)
Leucine-enriched hypercaloric hyperproteic oral nutritional supplement
Patients will receive nutritional support with Leucine-enriched hypercaloric hyperproteic oral nutritional supplement
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard hypercaloric hyperproteic oral nutritional supplement
Patients will receive nutritional support with Standard hypercaloric hyperproteic oral nutritional supplement
Leucine-enriched hypercaloric hyperproteic oral nutritional supplement
Patients will receive nutritional support with Leucine-enriched hypercaloric hyperproteic oral nutritional supplement
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* cancer of different origin treated with systemic treatment chemo, radiotherapy or combination treatment t
* weight loss \>5% during the previous three months or \>10% during the previous six months
Exclusion Criteria
* life expectancy \< 2 weeks
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Maimónides Biomedical Research Institute of Córdoba
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aura Herrera
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aura D Herrera Martinez, PhD
Role: PRINCIPAL_INVESTIGATOR
IMIBIC-HURS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IMIBIC
Córdoba, Cordoba, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Sarcopenia-Leucina1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.